Engineered protein could reduce bleeding after heart attack, study finds

08/14/2014 | Science World Report

The investigational drug APT102 may reduce tissue damage and bleeding risk following a heart attack, according to a Washington University School of Medicine in St. Louis animal study in the journal Science Translational Medicine. The drug is an engineered version of the anti-inflammatory and anti-clotting protein apyrase.

View Full Article in:

Science World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC